• Crews KR, Hicks JK, Pui CH, Evans WE. 2012. Pharmacogenomics and individualized medicine: Translating science into practice. Clin Pharmacol Ther 92:467475.
  • Farrugia G, Weinshilboum RM. 2013. Challenges in implementing genomic medicine: The Mayo Clinic Center for Individualized Medicine. Clin Pharmacol Ther 94:204206.
  • Hamilton AB, Oishi S, Yano EM, Gammage CE, Marshall NJ, Scheuner MT. 2014. Factors influencing organizational adoption and implementation of clinical genetic services. Genet Med 16:238245.
  • Johnson JA, Burkley BM, Langaee TY, Clare Salzler MJ, Klein TE, Altman RB. 2012a. Implementing personalized medicine: Development of a cost-effective customized pharmacogenetics genotyping array. Clin Pharmacol Ther 92:437439.
  • Johnson JA, Roden DM, Lesko LJ, Ashley E, Klein TE, Shuldiner AR. 2012b. Clopidogrel: A case for indication-specific pharmacogenetics. Clin Pharmacol Ther 91:774776.
  • Leon MB, Baim DS, Popma JJ, Gordon PC, Cutlip DE, Ho KKL, Giambartolomei A, Diver DJ, Lasorda DM, Williams DO, Pocock SJ, Kuntz RE. 1998. A clinical trial comparing three antithrombotic-drug regimens after coronary-artery stenting. N Engl J Med 339:16651671.
  • Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias W, Braunwald E, Sabatine MS. 2009a. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 360:354362.
  • Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS. 2009b. Cytochrome P450 genetic polymorphisms and the response to prasugrel: Relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes. Circulation 119:25532560.
  • Mega JL, Simon T, Collet J, Anderson JL, Antman EM, Bliden K, Cannon CP, Danchin N, Giusti B, Gurbel P, Horne BD, Hulot J, Kastrati A, Montalescot G, Neumann F, Shen L, Sibbing D, Steg PG, Trenk D, Wiviott SD, Sabatine MS. 2010. Reduced-function CYP2C219 genotype and risk of adverse clinical outcomes among patients treated with clopidgrel predominantly for PCI: A meta-analysis. JAMA 304:18211830.
  • Price MJ, Berger PB, Teirstein PS, Tanguay JF, Angiolillo DJ, Spriggs D, Puri S, Robbins M, Garratt KN, Bertrand OF, Stillabower ME, Aragon JR, Kandazari DE, Stinis CT, Lee MS, Manoukian SV, Cannon CP, Schork NJ, Topol EJ, GRAVITAS Investigators. 2011. Standard- vs high-dose clopidogrel based on platelet function testing after percutaneous coronary intervention: The GRAVITAS randomized trial. JAMA 305:10971105.
  • Price MJ, Murray SS, Angiolillo DJ, Lillie E, Smith EN, Tisch RL, Schork NJ, Teirstein PS, Topol EJ, GIFT Investigators. 2012. Influence of genetic polymorphisms on the effect of high- and standard-dose clopidogrel after percutaneous intervention: The GIFT (Genotype Information and Functional Testing) study. J Am Coll Cardiol 59:19281937.
  • Pulley JM, Denny JC, Peterson JF, Bernard GR, Vnencak-Jones CL, Ramirez AH, Delaney JT, Bowton E, Brothers K, Johnson K, Crawford DC, Schildcrout J, Masys DR, Dilks HH, Wilke RA, Clayton EW, Shultz E, Laposata M, McPherson J, Jirjis JN, Roden DM. 2012. Operational implementation of prospective genotyping for personalized medicine: The design of the Vanderbilt PREDICT project. Clin Pharmacol Ther 92:8795.
  • Reese ES, Mullins CD, Beitelshees AL, Onukwugha E. 2012. Cost-effectiveness of cytochrome P450 2C19 genotype screening for selection of antiplatelet therapy with clopidogrel or prasugrel. Pharmacotherapy 32:322332.
  • Scott SA, Sangkuhl K, Stein CM, Hulot JS, Mega JL, Roden DM, Klein TE, Sabatine MS, Johnson JA, Shuldiner AR. 2013. Clinical Pharmacogenetics Implementation Consortium guidelines for CYP2C19 genotype and clopidogrel therapy: 2013 update. Clin Pharmacol Ther 94:317323.
  • Wang L, Mcleod H, Weinshilbourm RM. 2011. Genomics and drug response. N Engl J Med 364:11431153.